Understanding how complement proteins affect autoimmune uveitis
Official title: New mechanisms by which complementýregulates the pathogenesis of experimental autoimmune uveitis
Funded at Cleveland Clinic Lerner Com-Cwru · NIH-10834908 · Data updated 2026-11-12
This study is looking at how certain proteins in the immune system affect a serious eye condition called autoimmune uveitis, which can cause blindness, and it's aimed at finding new ways to help prevent or lessen the impact of this disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cleveland Clinic Lerner Com-Cwru NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project start | May 1, 2021 |
| Project end | April 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $402,500 |
| NIH project number | 5R01EY032458-04 |
| Project ID | NIH-10834908 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with autoimmune uveitis or those at risk of developing this condition.
✕Less likely to help
Patients with non-autoimmune related eye conditions are unlikely to benefit from this research.
What this research studies
This research investigates the role of complement proteins in the development of experimental autoimmune uveitis (EAU), a condition that can lead to blindness. By studying mice with specific deficiencies in complement components, the researchers aim to uncover how these proteins influence the behavior of immune cells in the retina. The approach includes using gene knockout models and novel reagents to explore potential therapeutic targets for treating autoimmune uveitis. The ultimate goal is to identify new strategies to prevent or reduce the severity of this eye disease.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that prevent blindness caused by autoimmune uveitis.
How similar studies have gone: Previous research has shown promise in targeting complement proteins for autoimmune conditions, suggesting potential for success in this area.
Where this research is happening
-
Cleveland Clinic Lerner Com-Cwru
Cleveland, United States Active
Researchers
- Principal investigator: Lin, Feng C — Cleveland Clinic Lerner Com-Cwru
- Study coordinator: Lin, Feng C
Related research
Other NIH-funded projects on the same topics.
-
Adalimumab Dose Adjustment for Pediatric Uveitis in JIA
A pediatric study will test whether lowering how often kids with juvenile idiopathic arthritis–related uveitis take adalimumab can keep inflammation controlled while reducing side effects and cost.
-
Changing adalimumab dosing for children with juvenile arthritis–related eye inflammation
This project tries to see if giving lower or less frequent doses of adalimumab can keep eye inflammation under control in children with juvenile idiopathic arthritis.
-
Systemic and topical antiviral treatment for CMV anterior uveitis (STACCATO)
A new NIH-supported effort will test how well oral and eye-applied antiviral medicines control CMV-related anterior uveitis in affected patients.
-
Systemic and topical antiviral treatment for CMV anterior uveitis in patients
A patient-friendly look at using antiviral medicines to treat CMV-related eye inflammation and protect vision.
-
Systemic and topical antiviral treatment for CMV anterior uveitis
This project tests how oral and eye-drop antiviral medicines can help prevent vision loss from CMV-related eye inflammation in people with anterior uveitis.
-
Systemic and topical antiviral control of CMV anterior uveitis: TreatmentOutcomes
A patient-focused look at how CMV eye inflammation in adults could be treated with pills, eye drops, or other strategies to prevent vision loss.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.